LU91348I2 - Telbivudine et ses sels pharmaceutiquement acceptables - Google Patents

Telbivudine et ses sels pharmaceutiquement acceptables

Info

Publication number
LU91348I2
LU91348I2 LU91348C LU91348C LU91348I2 LU 91348 I2 LU91348 I2 LU 91348I2 LU 91348 C LU91348 C LU 91348C LU 91348 C LU91348 C LU 91348C LU 91348 I2 LU91348 I2 LU 91348I2
Authority
LU
Luxembourg
Prior art keywords
pentofuranonucleoside
deoxy
pharmaceutically acceptable
erythro
prodrug
Prior art date
Application number
LU91348C
Other languages
English (en)
Other versions
LU91348I9 (fr
Original Assignee
Idenix Cayman Ltd C7O Walkers
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91348(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idenix Cayman Ltd C7O Walkers, Centre Nat Rech Scient filed Critical Idenix Cayman Ltd C7O Walkers
Publication of LU91348I2 publication Critical patent/LU91348I2/fr
Publication of LU91348I9 publication Critical patent/LU91348I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
LU91348C 1998-08-10 2007-07-18 Telbivudine et ses sels pharmaceutiquement acceptables LU91348I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9611098P 1998-08-10 1998-08-10
US13135299P 1999-04-28 1999-04-28
PCT/US1999/018149 WO2000009531A2 (fr) 1998-08-10 1999-08-10 β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B

Publications (2)

Publication Number Publication Date
LU91348I2 true LU91348I2 (fr) 2007-09-18
LU91348I9 LU91348I9 (fr) 2018-12-31

Family

ID=26791121

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91348C LU91348I2 (fr) 1998-08-10 2007-07-18 Telbivudine et ses sels pharmaceutiquement acceptables

Country Status (22)

Country Link
US (5) US6395716B1 (fr)
EP (2) EP1104436B1 (fr)
JP (2) JP4294870B2 (fr)
KR (4) KR100634342B1 (fr)
CN (3) CN100387237C (fr)
AT (1) ATE313550T1 (fr)
AU (1) AU5475799A (fr)
BR (1) BRPI9912896B8 (fr)
CA (1) CA2340156C (fr)
CY (2) CY2007017I1 (fr)
DE (2) DE69929060T2 (fr)
DK (3) DK2415776T3 (fr)
ES (3) ES2579903T3 (fr)
FR (1) FR07C0046I2 (fr)
HK (3) HK1034083A1 (fr)
LU (1) LU91348I2 (fr)
MX (1) MXPA01001507A (fr)
NL (1) NL300286I2 (fr)
PT (2) PT2415776T (fr)
RU (1) RU2424016C2 (fr)
SG (1) SG132498A1 (fr)
WO (1) WO2000009531A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722214B2 (en) * 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
CA2340156C (fr) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1232166A2 (fr) * 1999-11-12 2002-08-21 Pharmasset Limited Synthese de 2'-deoxy-l-nucleosides
EP1634888A3 (fr) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthèse de 2'-désoxy-L-nucléosides
CZ303395B6 (cs) * 2000-02-29 2012-08-29 Bristol-Myers Squibb Co. Farmaceutický prostredek s nízkou dávkou entekaviru
WO2001067772A2 (fr) * 2000-03-09 2001-09-13 Videoshare, Inc. Partage d'une sequence video
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
CN100457118C (zh) 2000-04-13 2009-02-04 法玛塞特有限公司 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CN100490818C (zh) 2000-05-26 2009-05-27 诺瓦蒂斯有限公司 β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
NZ547204A (en) * 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN101250208B (zh) * 2000-11-29 2012-06-20 三井化学株式会社 L-核酸衍生物及其合成方法
EP1348712B1 (fr) * 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Procédés et intermédiaires dans la synthèse de L-thymidine
EP1569658A4 (fr) 2001-12-20 2007-05-30 Pharmassett Ltd Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
CA2470521A1 (fr) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. 7-deaza l-nucleosides en tant qu'antiviraux
EP1485395A4 (fr) * 2002-02-28 2011-04-13 Biota Scient Management Mimetiques nucleotidiques et leurs promedicaments
AU2003239088B2 (en) * 2002-06-27 2006-11-02 Medivir Ab Synergistic interaction of abacavir and alovudine
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA04012709A (es) 2002-06-28 2005-09-30 Idenix Cayman Ltd Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2005533824A (ja) * 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
SI1572095T1 (sl) * 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
KR101026294B1 (ko) * 2002-10-31 2011-03-31 메타베이시스 테라퓨틱스, 인크. 1,3-프로판-1-아릴 디올의 신규 시클릭 포스페이트디에스테르 및 프로드럭 제조에서의 이들의 용도
WO2004046331A2 (fr) * 2002-11-15 2004-06-03 Idenix (Cayman) Limited Nucleoside a ramification en 2’ et mutation de flaviviridae
WO2004052899A2 (fr) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Procede de production de nucleosides ramifies en position 2'
WO2004084453A2 (fr) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
KR20060015542A (ko) * 2003-04-28 2006-02-17 이데닉스 (케이만) 리미티드 산업 규모의 뉴클레오시드 합성
WO2004096197A2 (fr) * 2003-05-02 2004-11-11 Universita Degli Studi Di Cagliari 5-aza-7-deazapurine nucleosides pour le traitement de flaviviridae
WO2005003147A2 (fr) 2003-05-30 2005-01-13 Pharmasset, Inc. Analogues de nucleosides fluores modifies
MXPA06000162A (es) 2003-06-30 2006-03-21 Idenix Cayman Ltd Sintesis de ?-l-2-desoxinucleosidos.
CN1315863C (zh) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
EP1809301B1 (fr) 2004-09-14 2019-11-06 Gilead Pharmasset LLC Intermédiaires de d-ribonolactone à substitution 2-fluoro-2-alkyl
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP2007789B1 (fr) 2006-04-11 2015-05-20 Novartis AG Inhibiteurs spirocycliques du VIH/du virus de l'hépatite C
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP3222628A1 (fr) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Phosphoramidates nucléosidiques
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
KR101961601B1 (ko) * 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
CN102649788B (zh) * 2011-02-28 2015-03-25 四川大学 β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
ME03009B (fr) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Procédés permettant de traiter le virus de l'hépatite c (hcv)
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP2015508418A (ja) 2013-01-31 2015-03-19 ギリアド ファーマセット エルエルシー ２種の抗ウイルス化合物のコンビナトリアル製剤
EP4005560A1 (fr) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
WO2015123352A1 (fr) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN110680806A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 一种替比夫定颗粒的制备方法
CN108570078A (zh) * 2018-07-18 2018-09-25 荆门医药工业技术研究院 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875971A (en) 1959-01-14 1961-08-30 Hoffmann La Roche A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
WO1989002733A1 (fr) 1987-09-22 1989-04-06 The Regents Of The University Of California Analogues de nucleosides liposomiques pour le traitement du sida
DE3856557T2 (de) 1987-10-28 2004-06-03 Wellstat Therapeutics Corp. Acyldeoxyribonukleosid-Derivate und Verwendungen davon
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
JP2675864B2 (ja) 1988-07-05 1997-11-12 キヤノン株式会社 被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (fr) 1990-05-07 1991-11-14 Vical, Inc. Promedicaments lipidiques au salicylate et medicaments anti-inflammatoires non steroidiens
WO1991018914A1 (fr) 1990-05-29 1991-12-12 Vical, Inc. Synthese de derives de diphosphate et de triphosphate de glycerine
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
ATE133233T1 (de) 1990-07-12 1996-02-15 G Drill Ab Gesteinsbohrgerät mit hydraulischem antrieb im bohrloch
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
AU662130B2 (en) 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (fr) 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
EP0594677A4 (en) 1991-07-12 1997-09-17 Vical Inc Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU6402594A (en) * 1993-03-10 1994-09-26 Wellcome Foundation Limited, The Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
EP0746319A4 (fr) 1993-05-12 1997-11-05 Karl Y Hostetler Derives d'acyclovir a usage topique
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
JPH09504785A (ja) 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (fr) * 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NOUVEAUX β-L-NUCLEOSIDES ET LEUR UTILISATION
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
WO1999045935A1 (fr) * 1998-03-11 1999-09-16 Lipitek International, Inc. Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies
JP2002518452A (ja) 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
CA2340156C (fr) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CN100490818C (zh) * 2000-05-26 2009-05-27 诺瓦蒂斯有限公司 β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
NZ547204A (en) * 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses

Also Published As

Publication number Publication date
US6569837B1 (en) 2003-05-27
CY2007017I2 (el) 2009-11-04
KR20050062664A (ko) 2005-06-23
BRPI9912896B1 (pt) 2016-08-09
CY1116988T1 (el) 2017-04-05
KR20010072392A (ko) 2001-07-31
SG132498A1 (en) 2007-06-28
ES2255295T3 (es) 2006-06-16
DE122007000062I1 (de) 2007-12-20
EP1104436A2 (fr) 2001-06-06
AU5475799A (en) 2000-03-06
DK1431304T3 (en) 2015-03-02
CY2007017I1 (el) 2009-11-04
DE69929060D1 (de) 2006-01-26
HK1111913A1 (en) 2008-08-22
ES2579903T3 (es) 2016-08-17
BR9912896A (pt) 2002-02-13
EP2415776B1 (fr) 2016-05-25
DK2415776T3 (en) 2016-07-04
KR100568035B1 (ko) 2006-04-07
CA2340156C (fr) 2007-10-23
KR20060035817A (ko) 2006-04-26
FR07C0046I1 (fr) 2007-10-26
EP2415776A1 (fr) 2012-02-08
DE69929060T2 (de) 2006-08-31
BRPI9912896B8 (pt) 2021-05-25
FR07C0046I2 (fr) 2008-05-09
US7304043B2 (en) 2007-12-04
CN1257912C (zh) 2006-05-31
JP2002522552A (ja) 2002-07-23
KR100634342B1 (ko) 2006-10-16
US20060084624A1 (en) 2006-04-20
CA2340156A1 (fr) 2000-02-24
EP1104436B1 (fr) 2005-12-21
HK1097776A1 (en) 2007-07-06
KR100691737B1 (ko) 2007-03-12
LU91348I9 (fr) 2018-12-31
NL300286I2 (nl) 2008-01-02
PT1431304E (pt) 2015-03-09
MXPA01001507A (es) 2003-09-10
JP2007269798A (ja) 2007-10-18
US20080064655A1 (en) 2008-03-13
RU2006147216A (ru) 2008-07-10
US20030225028A1 (en) 2003-12-04
US6395716B1 (en) 2002-05-28
KR100702230B1 (ko) 2007-04-03
CN100482236C (zh) 2009-04-29
DK1104436T3 (da) 2006-04-03
CN1478483A (zh) 2004-03-03
CN1606983A (zh) 2005-04-20
WO2000009531A3 (fr) 2000-06-15
WO2000009531A2 (fr) 2000-02-24
CN1320128A (zh) 2001-10-31
ATE313550T1 (de) 2006-01-15
KR20060038483A (ko) 2006-05-03
PT2415776T (pt) 2016-07-07
ES2531928T3 (es) 2015-03-20
RU2424016C2 (ru) 2011-07-20
HK1034083A1 (en) 2001-10-12
CN100387237C (zh) 2008-05-14
NL300286I1 (nl) 2007-10-01
JP4294870B2 (ja) 2009-07-15

Similar Documents

Publication Publication Date Title
LU91348I2 (fr) Telbivudine et ses sels pharmaceutiquement acceptables
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
JP2004513070A5 (fr)
PL409123A1 (pl) Związki, ich zastosowanie i kompozycje do leczenia wirusowego zapalenia wątroby typu C
ATE136308T1 (de) Pyrimidin-nukleoside
PA8483101A1 (es) Compuestos quimicos
CY1112254T1 (el) Αρυλικοι φωσφοραμιδικοι εστερες νουκλεοζιτων και οι χρησεις τους ως αντι-ιικοι παραγοντες για την αντιμετωπιση του ιου της ηπατιτιδας c
MX9605809A (es) Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores.
ATE74603T1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
KR870006900A (ko) 항바이러스 조성물
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
ATE315574T1 (de) Nukleoside mit anti-hepatitis b virus wirkung
BRPI0409088A (pt) composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
HU901252D0 (en) Process for manufacturing of pharmaceutical compositions comprising purine derivatives
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
RU2001106651A (ru) Бета-l-2 - дезокси-нуклеотиды для лечения гепатита в
ATE321561T1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv- infektionsbehandlung
RU2001115094A (ru) Нуклеозиды, обладающие активностью против вируса гепатита в
KR890001560A (ko) 항바이어러스 조성물